U.S. Markets open in 8 hrs 16 mins

Heat Biologics, Inc. (HTBX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
7.42+0.06 (+0.82%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close7.36
Open7.39
Bid0.00 x 800
Ask0.00 x 1200
Day's Range7.23 - 7.55
52 Week Range3.22 - 30.10
Volume244,703
Avg. Volume2,545,148
Market Cap188.543M
Beta (5Y Monthly)0.32
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIRE

    Heat Biologics Provides Year-End Business Update

    DURHAM, NC / ACCESSWIRE / March 25, 2021 / Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today provided financial, clinical and operational updates for the year ended December 31, 2020.

  • ACCESSWIRE

    Heat Biologics to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference

    DURHAM, NC / ACCESSWIRE / March 8, 2021 / Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced that Jeff Wolf, CEO of Heat Biologics, has been invited to present at Inaugural Emerging Growth Virtual Conference, hosted by M Vest LLC and Maxim Group LLC.

  • HTBX: HS-110 Phase 2 Interim Data
    Zacks Small Cap Research

    HTBX: HS-110 Phase 2 Interim Data

    By John Vandermosten, CFA NASDAQ:HTBX READ THE PREVIOUS HTBX RESEARCH REPORT HS-110 Interim Data Heat Biologics, Inc. (NASDAQ:HTBX) announced positive interim survival data for its Phase II trial of HS-110 (viagenpumatucel-L), a cell-based therapy, in combination with leading checkpoint blockade inhibitors (CBIs). The trial was not a comparator trial; however, similarities in design with past